Celularity Inc. has reported its actual financial results for the year ended December 31, 2024. The company's total net revenues increased significantly to $54.220 million, compared to $22.771 million in the previous year. This growth was driven by a rise in product sales, which reached $35.336 million, up from $13.149 million the previous year. Additionally, revenues from licenses, royalties, and other sources grew to $13.744 million from $4.181 million. Despite the increase in revenues, Celularity Inc. continues to face financial challenges, as indicated by its accumulated deficit of $899.683 million, compared to $841.791 million the previous year. These results highlight the company's ongoing efforts to enhance its revenue streams through increased product sales and licensing agreements.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。